Haleos Labs Limi

{
  "main_header": {
    "sid": 1002809,
    "name": "Haleos Labs Limi",
    "stock_name": "Haleos Labs Limi",
    "full_name": "Haleos Labs Limited",
    "name_url": "stocks-analysis/haleos-labs-limi",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,410.20",
    "chg": -38.3,
    "chgp": "-2.64%",
    "dir": -1,
    "prev_price": "1,448.50",
    "mcapval": "434.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540679,
    "symbol": "HALEOSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE320X01016",
    "curr_date": "Jun 19, 03:30 PM",
    "curr_time": "04:34 AM",
    "last_traded_at": "Jun 19, 03:30 PM IST",
    "bse_nse_vol": "2.53 k",
    "exc_status": "Active",
    "traded_date": "Jun 19, 2026",
    "traded_date_str": "2026 06 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/haleos-labs-limi-1002809-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Haleos Labs Plummets 20.05% Amid Financial Setbacks and Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-plummets-2005-amid-financial-setbacks-and-heavy-selling-pressure-4051984",
        "imagepath": "",
        "date": "2026-06-13 16:13:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Sharp financial downturn reported; stock hits lower circuit at Rs.1,426.50</p>\n                    <p><strong>2 June:</strong> Continued heavy selling pressure drives price down to Rs.1,521.00 (-10.00%)</p>\n                    <p><strong>3 June:</strong> Further decline to Rs.1,510.00 (-0.72%) amid weak volume</p>\n                    <p><strong>4 June:</strong> Stock falls 7.28% to Rs.1,400.00 despite Sensex gains</p>\n                    <p><strong>5 June:</strong> Week closes at Rs.1,351.10, down 3.49% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><d..."
      },
      {
        "title": "Haleos Labs Limited is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-sell-4044023",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HaleosLabsLimit_mojoScore_4044023.png",
        "date": "2026-06-10 10:10:27",
        "description": "Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Haleos Labs Limited Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-hits-lower-circuit-amid-heavy-selling-pressure-4026083",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HaleosLabsLimit_stocks_hitting_lower_circuit_4026083.png",
        "date": "2026-06-01 10:00:31",
        "description": "At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price."
      },
      {
        "title": "Haleos Labs Limited Faces Sharp Financial Downturn Amidst Strong Market Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-faces-sharp-financial-downturn-amidst-strong-market-returns-4025014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/HaleosLabsLimit_fintrenddot_4025014.png",
        "date": "2026-06-01 08:00:56",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors."
      },
      {
        "title": "Are Haleos Labs Limited latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-haleos-labs-limited-latest-results-good-or-bad-4023944",
        "imagepath": "",
        "date": "2026-05-30 19:53:48",
        "description": "Haleos Labs Limited's latest financial results for Q4 FY26 reflect significant operational challenges and margin pressures. The company reported net sales of ₹75.14 crores, which represents a decline of 15.68% year-on-year and marks the lowest quarterly revenue in recent periods. This decline is accompanied by a substantial drop in net profit, which fell to ₹0.44 crores, reflecting an 85.19% decrease compared to the same quarter last year.\n\nThe operating profit margin, excluding other income, contracted sharply to 5.54% from 14.82% in the previous quarter, indicating severe margin compression. This deterioration in profitability is further highlighted by the profit after tax margin, which fell to 0.45%, the lowest in years. The company's operational metrics suggest that elevated employee costs and a significant increase in the tax rate to 61.54% have contributed to the decline in profitability.\n\nDespite a p..."
      },
      {
        "title": "Haleos Labs Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Resilience",
        "link": "https://www.marketsmojo.com/news/result-analysis/haleos-labs-q4-fy26-sharp-profit-decline-raises-concerns-despite-revenue-resilience-4022854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_quaterlyResult_4022854.png",
        "date": "2026-05-29 22:24:32",
        "description": "Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects."
      },
      {
        "title": "Haleos Labs Limited is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/haleos-labs-limited-is-rated-hold-4018046",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_mojoScore_4018046.png",
        "date": "2026-05-28 10:10:04",
        "description": "Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance."
      },
      {
        "title": "Haleos Labs Limited Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-technical-momentum-shifts-signal-bullish-outlook-amid-mixed-indicators-4010000",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_technicaldot_4010000.png",
        "date": "2026-05-25 08:03:09",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential."
      },
      {
        "title": "Haleos Labs Limited Technical Momentum Shifts Signal Mildly Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/haleos-labs-limited-technical-momentum-shifts-signal-mildly-bullish-outlook-4004382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/HaleosLabsLimit_technicaldot_4004382.png",
        "date": "2026-05-22 08:03:50",
        "description": "Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Sell to Hold. The stock’s recent performance, buoyed by bullish signals on multiple timeframes, contrasts with some cautionary monthly indicators, reflecting a nuanced outlook for investors."
      }
    ],
    "total": 455,
    "sid": "1002809",
    "stock_news_url": "https://www.marketsmojo.com/news/haleos-labs-limited-1002809"
  },
  "announcements": [
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding Board meeting held on November 14, 2019.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Outcome of Board Meeting",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding 'Update on Ranitidine HCL'.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Updates",
      "datetime": "04-Nov-2019"
    },
    {
      "details": "SMS Lifesciences India Limited has informed the Exchange regarding 'Certificate under regulation 74(5) of SEBI(DP)Regulations,2018'.",
      "source": "NSE",
      "caption": "SMS Lifesciences India Limited - Updates",
      "datetime": "22-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Haleos Labs Limited has declared <strong>15%</strong> dividend, ex-date: 24 Sep 25",
          "dt": "2025-09-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Haleos Labs Plummets 20.05% Amid Financial Setbacks and Heavy Selling Pressure

2026-06-13 16:13:18

Key Events This Week

1 June: Sharp financial downturn reported; stock hits lower circuit at Rs.1,426.50

2 June: Continued heavy selling pressure drives price down to Rs.1,521.00 (-10.00%)

3 June: Further decline to Rs.1,510.00 (-0.72%) amid weak volume

4 June: Stock falls 7.28% to Rs.1,400.00 despite Sensex gains

5 June: Week closes at Rs.1,351.10, down 3.49% on the day

Week Open

Read full news article

Haleos Labs Limited is Rated Sell

2026-06-10 10:10:27

Haleos Labs Limited is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Haleos Labs Limited Locks at Lower Circuit With 9.8% Loss — Sellers Queue, No Buyers in Sight

2026-06-01 10:00:31

At Rs 1,426.5, sellers were still queuing — but there were no buyers willing to take the other side. Haleos Labs Limited locked at its lower circuit of 9.79% on 1 Jun 2026, with unfilled sell orders and a frozen price.

Read full news article

Haleos Labs Limited Faces Sharp Financial Downturn Amidst Strong Market Returns

2026-06-01 08:00:56

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. Despite the company’s shares outperforming the broader market indices over multiple time horizons, key profitability and revenue metrics have taken a marked downturn, signalling challenges ahead for investors.

Read full news article

Are Haleos Labs Limited latest results good or bad?

2026-05-30 19:53:48

Haleos Labs Limited's latest financial results for Q4 FY26 reflect significant operational challenges and margin pressures. The company reported net sales of ₹75.14 crores, which represents a decline of 15.68% year-on-year and marks the lowest quarterly revenue in recent periods. This decline is accompanied by a substantial drop in net profit, which fell to ₹0.44 crores, reflecting an 85.19% decrease compared to the same quarter last year. The operating profit margin, excluding other income, contracted sharply to 5.54% from 14.82% in the previous quarter, indicating severe margin compression. This deterioration in profitability is further highlighted by the profit after tax margin, which fell to 0.45%, the lowest in years. The company's operational metrics suggest that elevated employee costs and a significant increase in the tax rate to 61.54% have contributed to the decline in profitability. Despite a p...

Read full news article

Haleos Labs Q4 FY26: Sharp Profit Decline Raises Concerns Despite Revenue Resilience

2026-05-29 22:24:32

Haleos Labs Limited reported a consolidated net profit of ₹0.44 crores for Q4 FY26, representing a dramatic decline of 93.35% quarter-on-quarter and 85.19% year-on-year, raising serious questions about the pharmaceutical company's operational efficiency and profitability trajectory. The micro-cap company, with a market capitalisation of ₹517.00 crores, saw its shares trade at ₹1,689.95 on May 29, 2026, up 3.68% from the previous close, suggesting investors may be looking past the disappointing quarterly performance towards potential recovery prospects.

Read full news article

Haleos Labs Limited is Rated Hold

2026-05-28 10:10:04

Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market performance.

Read full news article

Haleos Labs Limited Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators

2026-05-25 08:03:09

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. Despite some bearish signals on the weekly and monthly RSI, the stock’s overall technical indicators suggest a strengthening upward trajectory, supported by robust moving averages and bullish MACD readings. This nuanced technical landscape offers investors a complex but promising outlook on the stock’s near-term potential.

Read full news article

Haleos Labs Limited Technical Momentum Shifts Signal Mildly Bullish Outlook

2026-05-22 08:03:50

Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, prompting an upgrade in its Mojo Grade from Sell to Hold. The stock’s recent performance, buoyed by bullish signals on multiple timeframes, contrasts with some cautionary monthly indicators, reflecting a nuanced outlook for investors.

Read full news article

View All News